At the end of January 2025, the U.S. government revealed its intention to impose duties on imported computer chips, pharmaceuticals, and steel. This move seeks to strengthen the domestic manufacturing sector and tackle trade imbalances. Nonetheless, these actions may substantially impact international trade relations, especially concerning major U.S. partners in Asia.
In late January 2025, the U.S. administration announced plans to implement tariffs on imported computer chips, pharmaceuticals, and steel. This initiative aims to bolster domestic manufacturing and address trade imbalances. However, such measures could have significant implications for international trade dynamics, particularly affecting key U.S. allies in Asia.
The semiconductor industry is set to be notably impacted by these planned tariffs. Asia leads in worldwide chip production, producing over 80% of the planet’s semiconductors. Prominent firms such as Taiwan Semiconductor Manufacturing Co. (TSMC) and South Korea’s Samsung Electronics along with SK Hynix are key suppliers to the American market. For example, TSMC, recognized as the largest contract chip manufacturer internationally, earns about 70% of its revenue from North American customers, including tech powerhouses like Nvidia and Apple. Although TSMC is investing in a $65 billion production facility in Arizona, most of its output still occurs in Taiwan, which exposes it to the proposed tariffs. In a similar vein, Samsung and SK Hynix, which together hold around 75% of the global DRAM market, might encounter obstacles due to their significant exports to the United States.
Apprehensions in the Pharmaceutical Industry
The pharmaceutical sector is another central target of the suggested tariffs. Japanese pharmaceutical firms, such as Takeda, Astellas, Daiichi Sankyo, and Eisai, hold substantial interests in the American market. For instance, Takeda disclosed that more than half of its revenue in the previous fiscal year was from the U.S., whereas Astellas noted that 41% of its income was derived from the American market. Tariffs on imported pharmaceuticals could interfere with their operations and financial outcomes, possibly resulting in higher costs for consumers in the U.S.
The pharmaceutical industry is another focal point of the proposed tariffs. Japanese pharmaceutical companies, including Takeda, Astellas, Daiichi Sankyo, and Eisai, have significant stakes in the U.S. market. For example, Takeda reported that over half of its revenue in the last financial year originated from the U.S., while Astellas indicated that 41% of its revenue came from the U.S. market. Tariffs on imported pharmaceuticals could disrupt their operations and financial performance, potentially leading to increased costs for U.S. consumers.
Steel Industry and Broader Economic Implications
International Trade Ties and Possible Retaliation
The suggested tariffs have raised apprehensions among U.S. allies in Asia. Nations such as Taiwan, South Korea, and Japan, which play crucial roles in the global supply chains for semiconductors and pharmaceuticals, could face economic hurdles due to diminished competitiveness in the U.S. market. These countries might attempt to negotiate exemptions or contemplate imposing retaliatory tariffs on U.S. exports, potentially initiating a series of trade conflicts.
Consideraciones Económicas Nacionales
Domestic Economic Considerations
While the tariffs aim to promote domestic manufacturing, they could have mixed effects on the U.S. economy. Importers are likely to pass increased costs onto consumers, leading to higher prices for goods such as electronics and medications. Additionally, industries dependent on imported components may face challenges in sourcing materials, potentially hindering production and innovation. Economists caution that such protectionist measures could disrupt supply chains and may not yield the intended benefits of job creation in the targeted industries.
